CHINESE FOREIGN INVESTMENT OPPORTUNITIES
A number of pharmaceutical enterprises in Shijiazhuang, the capital of China's Hebei Province, will seek investment from Belgian, German, French and Dutch companies for new projects for the production of medicines and associated raw materials, reports the Beijing Review.
The Shijiazhuang New High-Technology Development Zone Medicine Research Institute is seeking investment worth some $3.94 million for the local construction of a research institute, a pharmaceutical factory and a hospital.
The Shijiazhuang Number 1 Pharmaceutical Factory will require total investment of $39 million for the development and production of various kinds of medicines, such as cephalosporins, while the Shijiaz-huang Number 4 Factory hopes to acquire investment totalling $3 million for the development and production of new infusion products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze